Simplification / Commercialisation Sample Clauses

Simplification / Commercialisation. “In partnership with enterprise agencies and Interface…demonstrably simplified business access to the knowledge and expertise in Scottish universities” • Aberdeen participates in the UIF Challenge Fund network, organised by the UIF Collaboration Manager which focusses on opportunities for Scottish universities and industry to work collaboratively. • The University will continue to provide opportunities for partnership working with industry sectors, in particular with the ACRD partners, with an emphasis on developing more strategic relationships with shared goals, and demonstrating to businesses the long term benefits of partnership. • A programme of training for researchers focused on the collaborative competencies to enhance engagement with businesses and impact from research will continue. • Aberdeen continues to support the simplification of processes and promoting efficient commercialisation, as demonstrated by our commitment to using standard templates wherever possible and our track record in commercialisation. Aberdeen is a member of the Universities Scotland RCDG Contracts Sub-Group which has already provided a range of commonly used contracts supporting simplification and harmonisation of the process for businesses to access knowledge within all universities. The University will continue to promote good practice within the partnership with the ACRD and other multi party collaborations. • Key priorities for 2022/23 include reviewing the University’s framework and policies for supporting knowledge exchange against best practice in the sector • The University plans to enhance the team supporting enterprise, innovation and business engagement under the leadership of the Vice-Principal for Regional Engagement • The University will work in the regional Triple Helix Group with NHS Grampian, RGU and ONE to identify and exploit opportunities for collaborative working. • The ECITB approved CPD course on Introduction to Offshore Decommissioning was delivered three times in 2021/22 and will be run again in 2022/23. An IChemE approved course on Biological Wastewater Treatment and Anaerobic Digestion is available online on demand. In 2023, the University will co-host the 13th International Gut Microbiome Conference in Aberdeen. Further CPD courses on Energy Transition and CCUS are in development for 2022/23 or 2023/24.
Sample 1
AutoNDA by SimpleDocs
Simplification / Commercialisation. In 2016 UWS developed three strategic themes around which it will focus teaching, research and enterprise activity: Sustainability, Health and Society. These themes have been a catalyst for cross disciplinary collaboration which is driving greater engagement with many of the Innovation Centres, Interface and with the Scottish Government’s proposed innovation reforms. UWS has had a particular focus on knowledge exchange in 2015/16, represented in part by our enhanced participation in schemes such as Knowledge Transfer Partnerships and Innovation Vouchers. From 15 to 16 UWS rose 20 places in the UK ranking table to be #3 in Scotland for KTP. In addition UWS accounted for 15% of the overall innovation voucher schemes run in Scotland which was 5% up on the previous year and ranked us among the top HEIs for the year. UWS sits on the Innovation Scotland Action Plan Implementation Group and is helping to lead the delivery of the important outcomes associated with this plan including a 16% increase in Start Ups in year One, the templating of contract types across all HEIs and the development of sector HEI liaison.  Target: We plan to continue this exceptional level of engagement and to maintain this grow level of 5% per annum.  Target: UWS is working towards a target of 15 start ups and spin outs by 2020
Sample 1

Related to Simplification / Commercialisation

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Trials The Ship shall run the following test and trials:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time.

  • Manufacturing Standards All forest products except poles, produced and sold under this contract will be manufactured to maximize the amount of logs meeting preferred log lengths and to achieve the average log length listed. Agreement No. Sort # Scaling Rule 97318 3 WS Average Log Length Preferred Log Lengths "WS" indicates that west side scaling rules apply. Minimum trim is 8 inches per scaling segment for west side scaling rules. "ES" indicates that east side scaling rules apply. Minimum trim is 4 inches per scaling segment for east side scaling rules. Poles produced under this contract will be manufactured to ANSI specifications (American National Standard Specifications and Dimensions for Wood Poles), in force at the time of signing this contract.

  • Synchronisation Commissioning and Commercial Operation 8.1 The Developer shall provide at least forty (40) days advanced preliminary written notice and at least twenty (20) days advanced final written notice to ESCOM of the date on which it intends to synchronize the Power Project to the Grid System.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Regulatory Approval 25.1 The Parties understand and agree that this Agreement and any amendment or modification hereto will be filed with the Commission for approval in accordance with Section 252 of the Act and may thereafter be filed with the FCC. The Parties believe in good faith and agree that the services to be provided under this Agreement are in the public interest. Each Party covenants and agrees to fully support approval of this Agreement by the Commission or the FCC under Section 252 of the Act without modification.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

Time is Money Join Law Insider Premium to draft better contracts faster.